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SummAry 
The CD31 (platelet endothelial cell adhesion molecule-1 [PECAM-1]/endothelial  cell adhesion 
molecule [endoCAM]) molecule expressed on leukocytes, platelets, and endothelial cells is postulated 
to mediate adhesion to endothelial ceUs and thereby function in immunity, inflammation, and 
wound healing.  We report the following novel features of CD31 which suggest  a role for it 
in adhesion amplification of unique T cell subsets: (a) engagement of CD31 induces the adhesive 
function of/31  and/~2 integrins;  (b) adhesion induction by CD31 immunoglobulin G (IgG) 
monoclonal antibodies (mAbs) is sensitive, requiring only bivalent mAb; (c) CD31 mAb induces 
adhesion rapidly, but it is transient;  (d) unique subsets of CD4 + and CD8 + T  cells express 
CD31,  including all naive (CD45RA +) CD8  T  cells; and (e) CD31  induction is selective, 
inducing adhesive function of fll integrins, particularly very late antigen-4, more efhciently than 
the f12 integrin lymphocyte function-associated  antigen-1.  Conversely, CD3 is more effective 
in inducing ~2-mediated adhesion.  Taken together, these findings indicate that unique T  cell 
subsets express CD31, and CD31  has the capacity to induce integrin-mediated adhesion of T 
cells in a sensitive and selective fashion. We propose that, in collaboration with other receptors/ 
ligands, CD31 functions in an "adhesion cascade" by amplifying integrin-mediated adhesion of 
CD31 + T  cells to other cells, particularly  endothelial calls. 
l~ 
gulated adhesion is critical to virtually all the functions 
oft lymphocytes. These functions inchde both antigen- 
independent processes such  as  lymphocyte recircnlation/ 
homing and antigen-specific  recognition events. Consequently, 
evolution has provided multiple modes of regulation of T 
cell adhesion.  These include regulated expression of the T 
cell adhesion receptors such as very late antigen (VLA) 1 inte- 
1 Abbreviations used in this paper: ELAM-1, endothelial leukocyte adhesion 
molecule-I; FN, fibronectin; HEV, high endothelial venule; HSA, human 
serum albumin; ICAM-1, intracetlular adhesion molecule-I; LN, laminin; 
PECAM-1, platelet endothelial cell adhesion molecule-I; VCAM-1, vascular 
cell adhesion  molecule-I; VLA, very late antigen. 
grins and L-sdectin (LAM-1/Leu-8); regulated expression of 
the ligands such as intracellular adhesion molectde-1 (ICAM-1), 
vascular cell adhesion molecnle-1 (VCAM-1), and E-sdectin 
(endothelial leukocyte adhesion molecule-1 [ELAM-1]); and 
regulated function of the T  cell adhesion receptors. 
It is rapidly becoming apparent that this last mode of regu- 
lation, namely regulated function of the adhesion receptors, 
is powerful and widely used, not only by T cells, but by other 
cell types (1-10). Regulated function is a prominent charac- 
teristic of the integrin adhesion molecules, which are a di- 
verse family of heterodimeric adhesion receptors used by vir- 
tually all cell types in adhesion to other cells and to extracellular 
matrix (11-14). Resting T calls express at least five integrins 
(11, 15). LFA-1 (c~LB2), the best known integrin on resting 
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three distinct ligands: ICAM-1, ICAM-2, and ICAM-3 (12, 
16). In addition, there are four ~1 integrins (VLA-3, VLA-4, 
VLA-5, and VLA-6) that mediate adhesion both to extracel- 
lular matrix via fibronectin (FN) and laminin (LN) (15) and 
to other cells via VCAM-1 (17).  It is remarkable that inte- 
grins on circulating ("resting") T cells do not mediate effec- 
tive adhesion. Dustin and Springer  (1) demonstrated that cross- 
linking of the CD3/TCR complex induces transient adhesion 
via LFA-1, and proposed that such regulated adhesion could 
account  for many  of the  adhesive  events  that  accompany 
antigen-specific T  cell recognition.  Thereafter,  the concept 
of regulated integrin  function on T  cells has been general- 
ized by extensions in a variety of directions: (a) the ~1 inte- 
grins show similar regulated function on resting T cells (15); 
(b) antigen-specific recognition induces ~1 integrin function 
on T cells (18); and (c) integrin function on T  cells is regu- 
lated not only by CD3 crosslinking (and the similar activa- 
tion stimulus provided by pairs of CD2 mAb), but also by 
crosslinking of other receptors on the T cell surface, including 
CD7, CD28, and CD44 (1,  15, 19, 20). These findings for 
T  cells have been both foreshadowed and complemented by 
a variety of findings regarding regulated function of integrins 
on other cell types including particularly platelets, granulo- 
cytes, and B cells  (3-7,  10). 
We use the terms adhesion "inducer" or "amplifier" to refer 
to a molecule on the T  cell surface that  augments integrin 
function. The nature of regulated adhesion makes the amplifier 
molecules as critical to the process as the adhesion molecule 
itself. In particular,  differential expression of such amplifier 
molecules will be as important  in T  cell differentiation  as 
differential expression of the adhesion molecule. The present 
report identifies CD31  as an amplifier molecule on unique 
subsets of T cells, and characterizes novel features of that adhe- 
sion induction. CD31 glycoprotein  (also designated PECAM-1, 
platelet endothelial  cell adhesion molecule) is an Ig super- 
family member that is most similar in structure to classical 
adhesion molecules such as ICAM-1, VCAM-1,  and neural 
cell adhesion molecule (NCAM) (21). It is expressed at high 
density on endothelium,  platelets, granulocytes, and mono- 
cytes (22-24).  It is also expressed by lymphocytes (23, 24). 
It has been implicated in cell-cell adhesion by a variety of 
findings.  It accumulates at contact regions between endothelial 
cells (22), transfection of CD31 into L cells causes them to 
aggregate (25), and CD31 mAbs inhibit endothelial cell con- 
tact, as well as transfected L cell aggregation (25). CD31 has 
been postulated to bind to CD31 in homophilic interactions, 
as well as to participate in heterophilic interactions involving 
proteoglycans (22,  26).  The present report  demonstrates  a 
role for CD31  in  adhesion induction  on T  cells,  and pro- 
poses a model of its potential involvement in an "adhesion 
cascade" on T  cells. 
Materials and Methods 
Human T Cell Subsets.  Highly purified CD4 T cells, CD8 T 
cells, and naive (CD45RA+CD45RO -) CD8 T cells were pre- 
pared from PBMC of volunteer research healthy donors by exhaus- 
tive immunomagnetic  negative selection, essentially as previously 
described (27). We routinely use Advanced Magnetic Particles (Ad- 
vanced Magnetics, Cambridge, MA) and/or Dynabeads (Dynal  Inc., 
Fort Lee, NJ),  and a cocktail of mAbs consisting of MHC class 
II mAb IVA12, CD19 mAb FMC63,  CD16 mAb VD2, CD11b 
mAb NIHllb-1, CD14 mAb 63D3, antiglycophorin  mAb 10F7, 
and CD4 mAb OKT4 or CD8 mAb B9.8.4  with  or without 
CD45RA mAb FMC71 (to negatively isolate memory T cells), 
or CD45RO mAb UCHL1 (to negatively isolate naive T cells) 
(27). The anti-HLA-DK mAb IVA12 was included in the selec- 
tion cocktail to exclude the normal low percentage of circulating 
activated T cells. Furthermore, the CD8 dull (dim) population which 
has YK-like features phenotypically and functionally (28), was also 
excluded from the CD8 § population  by the use of a separation 
cocktail containing  the CD16  mAb VD2 and the CD11b mAb 
NIHllb-1.  The purity of T  cell subsets were >96%  CD4 § or 
>94% CD8 +, and >99% CD45R.A + or >99% CD45RO §  as 
determined  by flow cytometric  analysis. 
Antibodies and other Reagents.  The following mAbs were used 
as purified Ig:  CD31-specific mAb NIH31-1 and NIH31-2 were 
generated and their specificity documented by binding  to CD31- 
transfectants  (data not  shown);  CD31  mAb PECAM-1.2  (P. J. 
Newman, unpublished observations), CD31 mAb 4G6 (S. M. A1- 
belch, unpublished observations), CD31 mAb SG134 (29) (S. Goyert, 
CorneU University Medical College, Manhasset, NY), CD31 mAb 
LAK1 (30) (M. Zocchi, Laboratory of Adoptive Immunotherapy, 
Milan, Italy), CD31 mAb L33 (D. Buck; Becton Dickinson & Co., 
San Jose, CA). Other mAb are as follows: CD11b mAb NIH11b-1, 
CD49d mAb NIH49d-1,  CD44 mAb NIH44-1  (31) and CD45 
mAb NIH45-2 (generated locally), CD3 mAb OKT3, CD4 mAb 
OKT4, CD14 mAb 63D3, class II mAb IVA12, CD7 mAb 3A1, 
antiglycophorin mAb 10F7 (all from American Type Culture Col- 
lection,  Kockville, MD), CD2 mAb 95-5-49 (R. K. Quinones, 
Children's Hospital Medical Center, Washington, DC), CD8 mAb 
B9.8.4 (B. Malissen, Centre National de la Recherche Scientifique, 
Marseilles, France), CD19 mAb FMC63, CD45RA mAb FMC71 
(H.  Zola, Flinders Medical  Center,  Bedford  Park, Australia), 
CD45KO mAb UCHL1 (P. Beverley, Courtauld Institute  of Bio- 
chemistry, London,  UK), CD18 mAb MHM23 (J. E. Hildreth, 
Johns Hopkins Medical School, Baltimore, MD). CD49d mAb L25 
(D. Buck), CD29 mAb MAB13, CD49e mAb MAB16 (both K. 
Yamada, National  Institute  of Dental Research, Bethesda, MD), 
CD28 mAb CLB-28/1  (K. van Lier, Centraal Laboratorium van 
de Bloedtransfusiedienst  (CLB) Amsterdam,  The Netherlands), 
CD16 mAb VD2 (A. E. G. K. von dem Borne, CLB, Amsterdam, 
The Netherlands). CD31 polyclonal Ab PECAM IgG was prepared 
by Protein A affinity chromatography from polyclonal rabbit anti- 
CD31 antisera (25, 32). IgG was present at 10 #g/ml final concen- 
tration  throughout the assays, except for CD28 mAb which was 
used at a 1:1000 concentration  which is functional in other assays. 
Purified soluble VCAM-1 was prepared as previously described 
(33). Human FN was obtained from New York Blood Center, New 
York. ICAM-1 was purified by affinity chromatography  from the 
Reed-Sternberg cell line L428 as previously described (34). Col- 
lagen type I and fibrinogen type I as control  were bought from 
Sigma Chemical Co., (St. Louis, MO). VCAM-l-transfected L cells 
and mock transfectant  L cells were also prepared as previously 
reported  (25, 35). 
Adhesion Assay.  Adhesion assays were performed essentiaUy  as 
previously described (15). Purified VCAM-1 (80 ng/well),  FN (1 
gg/weU),  ICAM-1  (6  ng/well),  collagen  type  I  (1  gg/well), 
fibrinogen type I (1 gg/well), and control BSA (3% solution) were 
applied to 96-well microtiter  plates (Costar, Cambridge,  MA) in 
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subsequently blocked with Ca/Mg-free PBS/3% BSA for 2-3 h 
at 37~  to reduce nonspecific attachment. L ceils were plated onto 
96-well  plates  (Costar)  and cultured to confluence. Plates  were 
washed three times with PBS before the addition of 50,000 SlCr- 
labeled T ceils to each well in a final volume of 100/zl PBS/0.5% 
human serum albumin (HSA). mAbs (1/zg/weil) were added to 
relevant wells. After a settling phase of 30 min at 4~  which also 
allowed mAb binding,  plates  were rapidly warmed to 37~  for 
15 min, and nonadherent ceils were washed off. Well contents were 
lysed with 1% Triton X-100, and 3' emissions of well contents de- 
termined. Background binding of T cells to BSA or collagen was 
1-7%. Data were expressed as mean percentage and SE of binding 
of T cell subsets  from representative individuals.  Crosslinking of 
CD3 and CD31 on T ceils or T cell subsets was performed as de- 
scribed (15) by 30 min preincubation with relevant mAbs at 4~ 
and washing before addition to triplicate wells containing 0.05/~g 
goat anti-mouse Ig. When not being crosslinked,  CD31 mAb was 
added at the beginning of the settling phase. 
Flow Microfluorometry.  Staining and flow cytometric analysis 
were carried out by standard procedures (36) using FACS-II  |  (Becton 
Dickinson & Co., Mountain View,  CA). The mAbs used were 
CD45RA  mAb  Leu-18-FITC  and  CD31  mAb  SG134  (29). 
Amplification was provided by a three-decade logarithmic amplifier. 
Results and Discussion 
CD31 Is Expressed on Unique Subsets ofT Cells.  The com- 
plexities of T  cell migration/homing  are most readily un- 
derstood in terms of regulated adhesion of different T  cell 
subsets to different apposing surfaces, particularly endothelial 
calls.  Our previous studies have emphasized differential regu- 
lation of adhesion molecules on different T  cell subsets, and 
their relevance to call-cell adhesion (2). Our interest in CD31 
was first stimulated by observing that  CD31  was differen- 
tially expressed on subsets of circulating T  ceUs. Our com- 
parisons between CD31 and other markers of T  cell subsets 
indicate that CD31 is expressed on unique subsets of T  ceils 
(Fig.  1).  CD31  heterogeneity does  not  correlate precisely 
with either of the two best understood dichotomies within 
T cells: CD4 vs. CD8 and CD45RA ("naive") vs. CD45KO 
("memory"). Nevertheless,  there are biases towards higher 
frequency of CD31 +  cells among  CD8 +  calls and  among 
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Figure 2.  Multiple  CD31 mAbs induce adhesion of T cells  but control 
mAbs do not. Binding of slCr-labeled naive (CD45RA +) CD8 T cells 
to purified FN (A) and VCAM-1 (B) was assessed in the presence of the 
following stimuli: CD31 mAb or PECAM polyclonal  anti-CD31 IgG (cross- 
hatched Mrs), 10 ng/ml PMA (open bars), and control mAb (filled bars). 
No additional crosslinking agent was added. Data are expressed as mean 
percentage and SE of binding of T cells from three replicate  wells. (Dotted 
line) Visual aid indicating binding of T cells to each ligand without mAb 
stimulus. 
CD45RA §  cells.  The conclusions from combined analysis 
of CD4/8 and CD45RA are that: among CD8 § cells, typi- 
cally 90% express CD31,  all of the naive (CD45KA +) cells 
and about half of the memory (CD45RA-)  cells (Fig. 1 B); 
and among CD4 cells, typically 20%  express CD31,  about 
half of the naive (CD45RA +) cells and few of the memory 
(CD45RA-)  cells (Fig.  1 A). This heterogeneity does not 
A  CD4  T  cells  B  CD8  T  cells 
I  1  I 
D  ~0  ~D  )0  40  50  |0 
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Figure  1.  Unique expression  of CD31 antigens on 
resting peripheral  T cell subsets. Histograms for CD31 
on naive (CD45RA +) subpopuhtions (dotted line) and 
memory (CD45RA-) subpopulations (solid line) of 
purified resting peripheral CD4 + cells (A) and CD8 + 
T  cells (B). Analyses were carded  out  with  the 
CD45RA  mAb Leu-18-FITC and the CD31 mAb 
SG134. The fraction of CD45RA + cells is 34% for 
the CD4 and 65% for the CD8 preparation. 
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cules whose expression we have examined on T  cells  (data 
not shown).  The bias toward CD31 expression on CD8 + 
cells and naive (CD45KA +) cells is remarkable since most 
adhesion molecules are similarly expressed on CD4 vs. CD8 
cells (Y. Tanaka,  unpublished observations), and of the many 
adhesion molecules differentially regulated on T  cells, most 
are preferentially expressed on memory (CD45RA-)  cells 
(2,  36-38). 
CD31 mAbs Induce Integrin-mediated Adhesion of  Resting Pe- 
ripheral Human T  Cells.  Preliminary studies demonstrated 
that  CD31  mAbs induced integrin-mediated  adhesion.  As 
expected,  the induction of adhesion by CD31 is seen only 
in purified  T  cell fractions  which  include CD31 §  T  cells 
(data not shown). Since CD31 is uniformly positive on naive 
(CD45RA +)  CD8  cells (Fig.  1),  we undertook  the most 
systematic analysis  of adhesion induction on that  subset of 
cells.  Purified  naive  (CD45RA +)  CD8  cells  show  aug- 
mented adhesion to the integrin  ligands FN and VCAM-1 
when CD31 mAbs are present during the assay (Fig. 2). The 
uniqueness of CD31 mAb-induced adhesion to each ligand 
is illustrated by the comparison with  six different control 
mAbs, four of which (CD7, CD28, CD3, and CD44) have 
been described to be inducers of integrin-mediated adhesion 
of T cells. None of these control mAbs cause marked induc- 
tion of adhesion in the absence of additional crosslinking (see 
below). In contrast,  adhesion is augmented by most of the 
CD31 mAbs without additional erosslinking. The two CD31 
mAbs that are least effective in induction of adhesion are the 
two mAbs that  bind to the most membrane-proximal  do- 
mains of CD31 (S. M. Albelda, unpublished observations). 
To confirm  that  T  cell binding  to purified immobilized 
ligand  is a valid model of integrin-mediated  adhesion,  the 
critical features of CD31-induced adhesion were reproduced 
for T cell binding to an L cell transfected with VCAM-1 (Fig. 
3). About 20% of the resting CD8 naive cells bound to the 
VCAM-1  transfectant,  and  this  binding  was  doubled  by 
pretreatment with CD31 mAbs. Since VCAM-1 is expressed 
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CD31 mAbs induce adhesion of T cells to VCAM-l-trans-  Figure  3. 
fected L cells. Binding of CD8 + T cells to VCAM-l-transfected L cells 
LVE3 (filled  bars) and mock-tramfeetant NED2-L cells (open bars) was as- 
sessed in the presence of CD31 mAb SG134, CD8 mAb B9.8.4, or PMA. 
Data are expressed as mean percentage and SE of binding of T cells from 
three replicate wells. 
on the transfected cells at a level severalfold lower than  on 
activated endothelial cells (data not shown), these data indi- 
cate that CD31-induced adhesion could be relevant to T cell 
adhesion  to VCAM-1 expressing endothelium. 
It is noteworthy that the adhesion induced by the best CD31 
mAbs approaches or equals that of PMA (Figs. 2 and 3), which 
is generally the strongest pharmacologic  inducer  of T  cell 
adhesion.  To determine whether PMA and CD31 mAbs might 
activate calls in a complementary fashion, cells were activated 
by both CD31  and PMA (Fig.  4 A).  The lack of demon- 
strable additive induction provided no evidence for distinct 
signaling  pathways or activation of distinct  subsets within 
this  relatively  homogenous  population  of  CD8  naive 
(CD45RA +) cells.  Additional controls in that  experiment 
demonstrate that  CD31-mediated induction does not non- 
specifically  alter adhesion of T  cells to otherwise irrelevant 
extracellular  matrix proteins  (Figs.  4, B  and  C). 
mAb blocking  studies  were performed  to  confirm  that 
CD31-induced adhesion to the three ligands (FN, VCAM-1, 
and ICAM-1) was mediated by the integrin receptors on T 
cells which normally bind these ligands (Fig. 5). As expected, 
T  cell binding to VCAM-1 and FN was mediated by inte- 
grins of the ~1 family, and binding to ICAM-1 was medi- 
ated by integrins  of the ~2 family.  More  specifically,  the 
VCAM-1 binding was mediated by VLA-4 and the FN binding 
A  VCAM-1 
NO MAB  --~ 
CD8 I 
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CD8+PMA 
CD31+PMA  I 
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C  Collagen 
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CD8 
CD31  PMA 
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Figure 4.  CD31 mAbs induce adhesion of T cells to VCAM-1, but 
not fibrinogen and collagen. Binding ofCD8 + T ~ls to purified VCAM-1 
(A), fibrinogen (B), and collagen (C) was assessed in the presence of the 
following  stimuli: CD31 mAb SG134,  CD8 mAb B9.8.4, PMA, or a com- 
bination of PMA with CD31 mAb. Data are expressed  as mean percentage 
and SE of binding of T cells from three replicate wells. 
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Figure 5.  mAb inhibition of CD31-induced adhesion. Binding of naive 
(CD45RA +) CD8 T  cells to FN (A),  VCAM-1 (B), and ICAM-1 (C) 
induced by the CD31 mAb NIH31-1  and SG134 was assessed in the ab- 
sence (open Mrs) or presence (filled bars) of the indicated purified mAb at 
10 #g/ml. Data are expressed as mean percentage  and SE of binding of 
T  calls from three replicate wells. (Dashed line) Background  binding of 
naive (CD45KA +) CD8 T  cells to control BSA. 
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Effect of additional crosslinking on CD31- or CD3-induced  Figure 6. 
adhesion  of T  cells. Binding of naive (CD45RA +) CD8 T  cells to FN 
(A) and VCAM-1 (B) induced by CD31 mAb SG134 or CD3 mAb OKT3 
was assessed in the absence (crosshatched bars) or presence (filled bars) of 
additional  crosslinking  with goat anti-mouse Ig. Data are expressed as 
mean percentage and SE of binding of T cells from three replicate wells. 
(Dashed line) Background binding of naive (CD45RA +) CD8 T cells to 
control proteins  (collagen in A  or BSA in B). 
was mediated primarily by VLA-5,  with a small contribu- 
tion from VLA-4. Functional inhibition by our newly gener- 
ated NIH49d-1 mAb was identical to that of the reference 
VLA-4 mAb L25. Thus, the interactions of VLA-4/VCAM-1, 
VLA-4/FN,  VLA-5/FN,  and LFA-1/ICAM-1 induced by 
CD31 mAbs are consistent with those observed with other 
T  cell populations and other inducing stimuli (19). 
The capacity of CD31 IgG mAbs to induce adhesion in 
the absence of additional crosslinking by a polyvalent anti-Ig 
reagent (Fig. 2) seems to be a fundamental characteristic  of 
CD31 IgG mAbs, which distinguish them from CD3 IgG 
mAbs, the prototypic inducers of T cell adhesion (1). When 
the issue of crosslinking is explored (Fig. 6), the results confirm 
that CD31 mAbs can induce in the absence of additional cross- 
linking, while CD3 IgG mAbs (and the other adhesion in- 
ducer molecules shown in Fig. 2) do not. CD31-induced adhe- 
sion is often augmented by crosslinking, but is almost always 
observed without it (Fig. 6, and data not shown). Thus, the 
CD31 "trigger" of adhesion appears to be a uniquely sensi- 
tive one requiring only dimer formation, since most CD31 
IgGs tested induce adhesion (Fig.  2).  Since Fab fragments 
of CD31 mAbs induce little adhesion (data not shown), the 
minimal stimulus in this system seems to be CD31 dimer 
formation, not receptor occupancy. 
The kinetics of CD31 induction of adhesion to VCAM-1 
were analyzed (Fig. 7). Induction by CD31 was rapid, regard- 
less of the presence or absence of additional crosslinking. In- 
duction by crosslinked CD3 was similar. The induced adhe- 
sion was gone by 60 min. Thus, the adhesion induced by 
CD31 resembles the rapid onset and decay of CD3-induced 
adhesion. This time course is consistent with models in which 
CD31-induced adhesion, like CD3-induced adhesion, plays 
a transient role in a coordinated sequence of events mediating 
T  cell adhesion. 
Differential Induction of Adhesion  by CD31  vs. CD3.  The 
fact that multiple surface molecules, including CD3, CD2, 
CD7, CD28, CD44, and now CD31 can regulate T cell adhe- 
sion, suggests that regulation of adhesion is a fundamental 
role served by a variety of cell surface molecules. Adhesion 
regulation would be most adaptive if different adhesion- 
inducing molecules preferentially regulated different adhesion 
receptors. We tested this possibility by comparing the ligand 
specificity of adhesion induced by erosslinked CD3 and CD31 
in multiple donors and experiments (Fig.  8).  Each  point 
represents the differential binding of a particular preparation 
of T  cells to two different ligands.  When CD3 is used as 
the inducer (o), the T cells preferentially adhere to ICAM-1, 
as indicated by their position above the diagonal. Conversely, 
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Figure  7.  The kinetics of CD31-induced adhesion to VCAM-1. Binding 
of naive (CD45RA +) CD8 T cells to purified VCAM-1 was assessed after 
the indicated duration (x axis)  of incubation  at 37~  with the following 
stimuli: continuous presence of the bivalent CD31 mAb SG134 (open circle 
and solid line); the crosslinked CD31 mAb SG134 (filled circle and solid line); 
the crosslinked CD3 mAb OKT3 (filled circle and dotted-dashed line); and 
without any simulation  (dashed line). (Dotted  line) Background  binding 
of naive (CD45RA *) CD8 T cells to BSA. Note that in this and all ex- 
periments,  the cells have been allowed to settle for 30 rain at 4~  before 
warming to 37~  The inducing stimulus is present during this 4~  prein- 
cubation. 
when CD31 is used as the inducer (O) the T cells bind pref- 
erentially to VCAM-1 and to FN. Differential induction was 
not due to differences in kinetics of response (Fig. 7, and data 
not shown). 
These findings of preferential induction have two impor- 
tant implications. First, they imply that there is more than 
one biochemical mechanism for integrin regulation. This com- 
plements the findings of Hermanowski-Vosatka and Wright 
(39) who have identified a unique lipid which augments adhe- 
sive function of/32 integrins, but not/31 integrins (S. Wright, 
personal communication). Our previous studies using phar- 
macologic inhibitors also indicate that there is more than one 
biochemical pathway for inducing/31 and/32 integrin func- 
tion (19). Taken together, these results suggest a rich diver- 
sity of mechanisms for selectively regulating adhesion via 
different integrins. This complexity is fully consistent with 
the growing conviction that adhesion regulation is very im- 
portant physiologically. In addition, these data on differen- 
tial induction imply that CD31 and CD3 have specialized 
roles in adhesion induction. CD3 is the critical adhesion in- 
ducer in antigen-specific recognition;/32 integrin-mediated 
binding to ICAM-1 on apposing cells may be particularly 
critical for this process.  On the other hand, CD31 may be 
critical to T  cell-endothelial cell interactions, as discussed 
below, fll integrin-mediated binding to VCAM-1, FN, and 
other ligands may be particularly important for T  cell-en- 
dothelial cell adhesion, and subsequent migration of T cells. 
For these studies we have used CD8+CD45RA + cells. A 
distinct, but equally interesting potential explanation is that 
despite their uniform expression of CD3 and CD31,  CD3 
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Figure  8.  Crosslinked CD3 and CD31 differentially induce the adhe- 
sion of T  cells to ligands  for/31  and/32  integrins.  Adhesion  of naive 
(CD45RA +) CD8 T  cells to ICAM-1, VCAM-1,  and FN was assessed 
after coating of T  cells with mAbs specific for CD3 or CD31 followed 
by crosslinking by GAMIg. (A) and (/3) show scatter plot analysis of in- 
duced percentage of cell binding to ICAM-1 vs. VCAM-1 (.4), and ICAM-1 
vs. FN (B) by crosslinked CD3 mAb (filled circle) or CD31 mAb (open 
circle). Symbols represent data from five (.4) or six (B) representative indi- 
viduals, distinguished by numbers adjacent to the circles. Data are expressed 
as (percent binding of mAb-induced cells -  percent binding of uninduced 
cells). 
preferentially induces LFA-1 function on some of these cells, 
and CD31  induces VLA-4 function in others. 
Previous studies have fostered the concept of CD31 as an 
adhesion molecule per se. The present studies add a new per- 
spective by showing that CD31 is an adhesion-inducing mol- 
ecule. We favor the concept that CD31 mediates both weak 
and potent adhesion-induction, allowing it to serve as an adhe- 
sion amplifier.  This kind of molecule would be the missing 
element in our understanding of T cell-endothelial cell adhe- 
sion as a cascade consisting of a coordinated series of receptor/ 
ligand interactions which includes: (a) initial tenuous adhe- 
sion (tethering); (b) triggering; (c) integrin-mediated strong 
adhesion (glue); and (d) subsequent detachment (8). Studies 
of granulocytes indicate that the initial tethering is usually 
served by molecules of the selectin family (40). L-selectin may 
function in that role for many T cells (41). Strong adhesion 
is most likely mediated by the integrins LFA-1 and VLA-4 
(2, 35,  42),  however, this cannot occur on resting T  cells 
in circulation until the integrins become functionally acti- 
vated. The intervening step by which the integrins become 
activated is  not  understood.  Obviously,  the CD3/T  cell 
receptor would not be expected to be involved in T cell-en- 
dothelial cell interactions. I~selectin is a good candidate, but 
has  not been shown to induce integrin function. 
CD31 is an excellent candidate for an adhesion amplifier 
in T  cell-endothelial cell interactions, given the adhesion- 
inducing capacity of CD31 shown in the present studies, and 
its demonstrated role in cell interactions with endothelial cells 
(22).  If analogous CD31 engagement occurs when CD31 + 
T  cells bind to endothelium, then our results predict that 
such CD31 crosslinking will induce integrin-mediated adhe- 
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phasized by the finding that dimer formation may be sufficient 
for triggering (Figs.  2 and 6) and that the adhesion induc- 
tion is transient (Fig.  7).  Furthermore, the relatively large 
number of Ig domains (six) in CD31 may allow it to pro- 
trude beyond much of the other glycocalyx, and thereby make 
its distal parts readily available early in cell-cell interaction. 
Our studies indicate that CD31  is particularly effective in 
inducing the function of VLA-4 integrin (even more so than 
VLA-5 and -6 integrins; data not shown). This finding fits 
well with concept of CD31 as an amplifier in T ceU-endothelial 
cell interactions, since it is increasingly apparent how impor- 
tant VLA-4 is in T cell interactions with endothelium in vitro, 
and ultimately in T cell recirculation in vivo (17, 35, 43-48). 
We are currently testing the hypothesis that CD31 contributes 
to T  cell-endothelial cell interactions. 
Recent in vivo  studies  in  the rat indicate effects of an 
anti-VLA-4 mAb on T cell movement into various sites, but 
most dramatically into gut (48).  Until now, there has been 
no explanation why there is such a predominance of CD8 
rather than CD4 cells (90% CD8) among intraepithdial lym- 
phocytes of the gut mucosa (49). We propose that the preferen- 
tial expression of CD31 on CD8 cells rather than CD4 cells 
(typically 80 vs. 20%),  together with its selective capacity 
to induce VLA-4 function, may contribute to the preferen- 
tial movement of CD8 cells into gut epithelium. In addition 
to the conventional VLA-4 molecule (oe4/31), there is an oL4- 
containing integrin (c~437) on gut-homing T  cells which 
mediates interactions with a ligand on specialized gut en- 
dothelium, Peyer's patch high endothelial venule (HEV) (50, 
51). It remains to be determined whether this integrin is also 
activated functionally by engagement of CD31. 
In the foregoing description of T cell-endothelial cell in- 
teractions, the postulated adhesion-amplifying role for CD31 
is analogous to the adhesion-amplifying role played by CD3 
in antigen-specific T  cell interactions (1). We view these as 
distinct but generally homologous adhesion cascades. More 
generally, we expect that there will be multiple T cell adhe- 
sion cascades. Each T  cell will have the potential for many 
adhesion cascades in its repertoire for use in interactions with 
different cells or extra cellular matrix. Different T cell subsets 
will have different specialized repertoires of adhesion cascades. 
Obviously, CD31 can be an inducer of adhesion only for those 
unique subsets of T cells which express it. It is also apparent 
that there must be and are other adhesion-inducing mole- 
cules on resting T  cells. 
Although the foregoing data prompt us to propose a spe- 
cial role for CD31 in T  cell-endothelial cell interactions in 
the gut, we suspect that it will also be important for T cells 
in other contexts. The preferential expression of CD31 on 
naive cells raises the possibility that it may contribute to the 
process of migration of naive cells into lymph node (52). Three 
lines of evidence indicate that VLA-4 ligands may exist in 
lymph node HEV, and therefore are consistent with this hy- 
pothesis. First, VCAM-1 can be expressed on endothdium 
in lymph nodes draining from sites of antigen stimulation 
(46). Second, VLA-4 mAb inhibits migration of several cate- 
gories of T cells to peripheral lymph node (48). Finally, inhi- 
bition studies with a peptide sequence from the III-CS site 
of FN indicate that it inhibits lymphocyte binding to cul- 
tured lymph node HEV (44). This suggests that VLA-4 may 
be involved in binding to a ligand on these HEVs. Thus, CD31 
and VLA-4 may be important for migration of some T cells 
through lymph node HEV.  Furthermore, given data that 
CD31 may participate in homophilic interactions with CD31 
(25), T cell CD31 may contribute to T cell interaction with 
not only CD31 + lymph node HEVs, which express CD31 
better  than  endothelial  cells  (53),  but  also  with  CD31 + 
APCs. Finally, Stockinger et al. (23) have demonstrated that 
CD31 mAbs induce reactive oxygen metabolites from mono- 
cytes. CD31 thus appears capable of contributing to the regu- 
lation of cellular processes  in addition to adhesion. 
It is evident that CD31 does not act alone, but rather in 
the context of other molecules which constitute the cascade. 
T cells floating in a sea of CD31 + cells in circulation do not 
have their integrins activated. Furthermore, only some of the 
CD31 + T  ceils become detectably adhesive when exposed 
to CD31 mAbs. Therefore, a permissive role for a suitable 
tethering molecule and potentially other cofactors is likely 
to be a prerequisite for physiologic CD31 triggering. We pre- 
dict a role for CD31 in T cell subset adhesion to specialized 
endothelial cells, where the combinatorial requirements of 
tether, trigger, and glue offer enormous flexibility in an adhe- 
sion cascade. 
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